A Wake Up Call about Obviousness-type Double Patenting – the Effect of In re Cellect

What many seem to have understood from Gilead Sciences, Inc. v. Natco Pharma Limited (Fed. Cir. 2014), has been clearly set forth in the recent...

MWZB Partner Ryan Pool to speak a AIPLA

We are proud to announce that Ryan Pool has been selected to speak at the AIPLA Mid-Winter Institute IP Practice in Japan Committee Pre-Meeting to be...

A Chipping Away of the Gilead Double Patenting Fiasco

The unorthodox reality presented by the broad Gilead decision in 2014 (Gilead Sciences, Inc. v. Natco Pharma Ltd. (Fed. Cir. 2014)) is that a patentee obtaining a second...

Are Proactive Portfolio Reviews Needed After 2015 Gilead Double Patenting Decision?

Gilead Sciences, Inc., Hoffmann-La Roche, Inc., F. Hoffmann-La Roche, Ltd., and Genentech, Inc., v.Natco Pharma Ltd.and Natco Pharma, Inc., 753 F.2d 1208 (Fed. Cir. 2014,...



MWZB Newsletter Signup